Analyst consensus rating
4D Molecular Therapeutics, Inc. Analyst Consensus Rating
FDMT analyst consensus rating, coverage count and price target evidence.
Direct answer
4D Molecular Therapeutics, Inc.'s consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $29.10.
Forecast evidence checked August 12, 2026.
Get free 4D Molecular Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.47
- Average price target
- $29.10
- High price target
- $37.00
- Low price target
- $17.00
- Target upside
- +153.7%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 12, 2026
- Valid through
- August 19, 2026